Enterprise Value
0.00
Cash
123.6M
Avg Qtr Burn
N/A
Short % of Float
4.54%
Insider Ownership
1.66%
Institutional Own.
16.43%
Qtr Updated
03/31/24
Drug Pipeline
Powered by
![](/BPIQ_Pill.png)
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
Larazotide Details COVID-19 | Phase 2 Data readout | |
Vurolenatide (NM-002) (GLP-1 Agonist) Details Bowel disorder, Rare diseases | Phase 2 Initiation | |
Larazotide Details Celiac disease, Autoimmune disease | Failed Discontinued |